American Society of Hirudotherapy

Heparin Versus Bivalirudin for Anticoagulation in Adult Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis

Wieruszewski PM, Macielak SA, Nei SD, Moman RN, Seelhammer TG, Nabzdyk CGS, Gerberi DJ, Mara KC, Hooten WM, Wittwer ED (2022) · ASAIO Journal

Review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
GRADE LowSystematic reviewBivalirudin: drug studies

Study Profile

Design
systematic review and meta-analysis of 6 retrospective observational studies (5 meta-analyzable)
Scope
Bivalirudin anticoagulation in adult ECMO
Main result
Heparin associated with more circuit-related thrombosis (OR 2.05, 95% CI 1.25-3.37, p=0.005) and higher mortality (OR 1.62, 95% CI 1.19-2.21, p=0.002) vs bivalirudin; no significant difference in major bleeding (OR 1.83, p=0.33)

Key Findings

  • Mayo Clinic-led methodologically rigorous synthesis
  • Heparin associated with 2-fold higher circuit thrombosis vs bivalirudin
  • 62% higher mortality signal with heparin
  • No significant difference in major bleeding events
  • Uses ROBINS-I risk-of-bias tool for transparency

Limitations

  • All 6 studies retrospective observational
  • Significant heterogeneity in bleeding endpoint (I²=82.7%)
  • Patient selection bias likely
  • Confidence intervals broad for some outcomes
  • Not applicable to whole-leech hirudotherapy

Clinical Implications

Wieruszewski 2022 contributes adult-specific evidence to the bivalirudin ECMO landscape. For ASH, this meta-analysis demonstrates how rigorous methodology applied to retrospective data can produce robust signals for the synthetic thrombin inhibitor pathway, distinct from the K040187 device-leech US clinical practice. The thrombosis and mortality signals strengthen the case for prospective RCT confirmation.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.